CN1761479A - 低分子量凝血酶抑制剂在降低胆固醇治疗中的应用 - Google Patents

低分子量凝血酶抑制剂在降低胆固醇治疗中的应用 Download PDF

Info

Publication number
CN1761479A
CN1761479A CNA2004800072860A CN200480007286A CN1761479A CN 1761479 A CN1761479 A CN 1761479A CN A2004800072860 A CNA2004800072860 A CN A2004800072860A CN 200480007286 A CN200480007286 A CN 200480007286A CN 1761479 A CN1761479 A CN 1761479A
Authority
CN
China
Prior art keywords
pab
aze
thrombin inhibitor
alkyl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800072860A
Other languages
English (en)
Chinese (zh)
Inventor
M·格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1761479A publication Critical patent/CN1761479A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pyrrole Compounds (AREA)
CNA2004800072860A 2003-03-22 2004-03-19 低分子量凝血酶抑制剂在降低胆固醇治疗中的应用 Pending CN1761479A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0306615.6A GB0306615D0 (en) 2003-03-22 2003-03-22 New use
GB0306615.6 2003-03-22

Publications (1)

Publication Number Publication Date
CN1761479A true CN1761479A (zh) 2006-04-19

Family

ID=9955311

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800072860A Pending CN1761479A (zh) 2003-03-22 2004-03-19 低分子量凝血酶抑制剂在降低胆固醇治疗中的应用

Country Status (17)

Country Link
US (1) US20060183692A1 (https=)
EP (1) EP1608311B1 (https=)
JP (1) JP2006520813A (https=)
KR (1) KR20050114237A (https=)
CN (1) CN1761479A (https=)
AT (1) ATE475417T1 (https=)
AU (1) AU2004222409B2 (https=)
BR (1) BRPI0408522A (https=)
CA (1) CA2517191A1 (https=)
DE (1) DE602004028348D1 (https=)
ES (1) ES2346969T3 (https=)
GB (1) GB0306615D0 (https=)
MX (1) MXPA05010159A (https=)
NO (1) NO20054285L (https=)
NZ (1) NZ542505A (https=)
WO (1) WO2004082702A1 (https=)
ZA (1) ZA200507614B (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237518B (it) * 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
AU2004222409A1 (en) 2004-09-30
CA2517191A1 (en) 2004-09-30
MXPA05010159A (es) 2005-11-16
HK1084329A1 (en) 2006-07-28
EP1608311A1 (en) 2005-12-28
JP2006520813A (ja) 2006-09-14
ZA200507614B (en) 2006-06-28
GB0306615D0 (en) 2003-04-30
NO20054285L (no) 2005-10-20
NO20054285D0 (no) 2005-09-16
KR20050114237A (ko) 2005-12-05
BRPI0408522A (pt) 2006-03-07
EP1608311B1 (en) 2010-07-28
DE602004028348D1 (de) 2010-09-09
US20060183692A1 (en) 2006-08-17
ES2346969T3 (es) 2010-10-22
NZ542505A (en) 2009-01-31
ATE475417T1 (de) 2010-08-15
WO2004082702A8 (en) 2005-03-24
WO2004082702A1 (en) 2004-09-30
AU2004222409B2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
CN1268339C (zh) Rosuvastatin(zd－4522)在制备治疗杂合家族性高胆固醇血症的药物中的应用
CN1196488C (zh) 3－羟基－3－甲基戊二酸单酰辅酶a还原酶抑制剂制造治疗糖尿病性神经病的药物的应用
CN1221259C (zh) Cs－866、氯沙坦和坎迪沙坦用于制备治疗动脉硬化的药物
CN1473566A (zh) 包含阿伐他汀和抗高血压药的联合疗法
CN1838949A (zh) 包含二甲双胍和他汀的组合的药物组合物
JP2012232995A (ja) 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
CN1658867A (zh) 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
WO2009147009A2 (en) Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
CN1422161A (zh) 新的β阻断剂与降胆固醇剂的组合物
CN1107707A (zh) 抑制体重增加或诱发体重减轻的方法
CN1777417A (zh) PPARα激动剂和二甲双胍降低血清甘油三酯的用途
CN1761479A (zh) 低分子量凝血酶抑制剂在降低胆固醇治疗中的应用
CN1889948A (zh) 他汀用于治疗代谢综合征的用途
CN101068548B (zh) 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法
CN1248692C (zh) 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途
EP1526894B1 (en) Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment
CN1688341A (zh) 降低血脂的药物组合物
CN1473042A (zh) 药物组合物
HK1084329B (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法
CN101057838A (zh) 预防和/或治疗高脂血症的药物
JP2007308484A (ja) 高脂血症の予防及び／又は治療のための医薬
HK1029530B (en) Combination pharmaceutical form comprising amlodipine and a statin compound
HK1029530A1 (en) Combination pharmaceutical form comprising amlodipine and a statin compound
CN1688314A (zh) 含有HMG－CoA还原酶抑制剂的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20060419

C20 Patent right or utility model deemed to be abandoned or is abandoned